CAJ | 학술논문

目的：观察华蟾素注射液灌注治疗肺癌晚期恶性心包积液的临床疗效。方法收治例经超声探查示大量心包积液的晚期肺癌患者，心包穿刺完全引流后向心包腔内灌注华蟾素～10ml/次，每周次，2周为周期，同时予以补液、利尿及维持电解质平衡等对症治疗。采用WHO制定的浆膜腔积液疗效评价标准和RECIST 1.1版非靶病灶评价标准评价客观疗效，采用美国癌症研究所常见毒性判定标准NCI CTC 3.0评价不良反应。结果例心包积液引流量平均为ml，积液均呈暗红色浓血性；心包腔内注药共次（平均次/例）。6例患者获完全缓解例，部分缓解例；同时心包填塞症状消失，一般情况明显改善。治疗期间无白细胞、血小板及血红蛋白下降等血液毒性反应，仅例有轻度消化道反应。结论华蟾素注射液灌注治疗晚期肺癌恶性心包积液可有效控制其增长，毒副作用小，可耐受，一定程度上能够改善患者的生活质量并延长生存，值得临床上借鉴。
목적：관찰화섬소주사액관주치료폐암만기악성심포적액적림상료효。방법수치례경초성탐사시대량심포적액적만기폐암환자，심포천자완전인류후향심포강내관주화섬소～10ml/차，매주차，2주위주기，동시여이보액、이뇨급유지전해질평형등대증치료。채용WHO제정적장막강적액료효평개표준화RECIST 1.1판비파병조평개표준평개객관료효，채용미국암증연구소상견독성판정표준NCI CTC 3.0평개불량반응。결과례심포적액인류량평균위ml，적액균정암홍색농혈성；심포강내주약공차（평균차/례）。6례환자획완전완해례，부분완해례；동시심포전새증상소실，일반정황명현개선。치료기간무백세포、혈소판급혈홍단백하강등혈액독성반응，부례유경도소화도반응。결론화섬소주사액관주치료만기폐암악성심포적액가유효공제기증장，독부작용소，가내수，일정정도상능구개선환자적생활질량병연장생존，치득림상상차감。
Objective To observe the curative effect of cinobufacini injection infusion therapy in advanced lung cancer with malignant pericardial effusion. Methods Six advanced lung cancer patients with malignant pericardial effusion were collected by echo-cardiography. The cinobufacini injection was perfused into pericardial cavity at a dose of 6-10ml twice a week with a two-week cycle af-ter draining all of the pericardial effusion. Meanwhile, the symptomatic treatments ( rehydration, diuresis, electrolyte balance, etc.) were given. The objective response was evaluated by effusion in serous cavities evaluation criteria established by WHO and response as-sessment in RECIST version 1.1. The adverse reactions were evaluated by NCI CTC 3.0. Results The effusion was dark red, concen-trated and bloody with average drainage flow of 800 ml each time. The pericardial effusion was under control after 24 times of pericardial cavity injections with 4 times for each patient at average. There were 4 cases of complete remission and 2 cases of partial remission. In addition to one patient with mild gastrointestinal reactions, there was no blood toxicity ( leucopenia, thrombocytopenia, decreased he-moglobin level, etc.). Conclusion Cinobufacini injection infusion therapy of advanced lung cancer with malignant pericardial effusion could control the pericardial effusion, improve the patient.s quality of life and prolong survival to a certain degree with few side effects. It is worthy of further clinical observational study.